Amanda Megan Cole

Names

Contact

Affiliations

• Office of Health Economics
  • website
  • location: London, United Kingdom

Research profile

author of:

• A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
  by Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin
• Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP)
  by A. Chapman & C. Taylor & A. Girling
• A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
  by Brockis, E. & Marsden, G. & Cole, A. & Devlin, N.
• Data Governance Arrangements for Real-World Evidence: South Korea
  by Lee, E. K. & Park, J. A. & Cole, A. & Mestre-Ferrandiz, J.
• How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
  by Cole, A. & Chan, A. & Mujoomdar, M. & Pichler, F. & Towse, A.
• Improving Efficiency and Resource Allocation in Future Cancer Care
  by 14 authorsCole, A. & Lundqvist, A. & Lorgelly, P. & Norrlid, H. & Karlsberg Schaffer, S. & Lewis, F. & Hernandez-Villafuerte, K. & Lindgren, P. & Garau, M. & Welin, K.-O. & Bianchi, S. & Althin, R. & O'Neill, P. & Persson, U. & Towse, A.
• Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?
  by Shah, K. & Chapman, A. & Devlin, N. & Barnsley, P.
• An Analysis of NICE Technology Appraisal Decisions 'Recommended in Line with Clinical Practice'
  by O'Neill, P. & Cole, A. & Duran, A. & Devlin, N.
• Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
  by Chapman, A. & Karlsberg Schaffer, S.
• "New Age" Decision Making in HTA: Is It Applicable in Asia?
  by Cole, A. & Marsden, G. & Devlin, N. & Grainger, D. & Lee, E. K. & Oortwijn, W.
• Data Governance Arrangements for Real-World Evidence
  by Cole, A. & Garrison, L. & Mestre-Ferrandiz, J. & Towse, A.
• Barriers to Uptake of Minimal Access Surgery in the United Kingdom
  by Cole, A. & O'Neill, P. & Sampson, C. & Lorgelly, P.
• Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment
  by Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin
• The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
  by Towse, A. & Cole, A. & Zamora, B.
• Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
  by Cole, A. & Towse, A. & Lorgelly, P. & Sullivan, R.
• Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
  by Cole, A. & Towse, A.
• Making Outcome-Based Payment a Reality in the NHS
  by Cole, A. & Cubi-Molla, P. & Pollard, J. & Sim, D. & Sullivan, R. & Sussex, J. & Lorgelly, P.
• Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
  by Cole, A. & Towse, A. & Zamora, B.
• Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
  by Cole, A. & Towse, A. & Zamora, B.
• Indication-Based Pricing (IBP) Consultation Report
  by Cole, A. & Towse, A. & Zamora, B.
• Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
  by Cole, A. & Towse, A. & Segal, C. S. & Henshall, C. & Pearson, S. D.
• NICE 'Optimised' Decisions: What is the Recommended Level of Patient Access?
  by Bulut, M. & O'Neill, P. & Cole, A.
• Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?
  by Paula Lorgelly & Jack Pollard & Patricia Cubi-Molla & Amanda Cole & Duncan Sim & Jon Sussex